MX2016007705A - Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo -8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il} metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4] triazina-1-carboxamida. - Google Patents
Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo -8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il} metil)-2-(prop-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4] triazina-1-carboxamida.Info
- Publication number
- MX2016007705A MX2016007705A MX2016007705A MX2016007705A MX2016007705A MX 2016007705 A MX2016007705 A MX 2016007705A MX 2016007705 A MX2016007705 A MX 2016007705A MX 2016007705 A MX2016007705 A MX 2016007705A MX 2016007705 A MX2016007705 A MX 2016007705A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- pyrazino
- octahydro
- azetidine
- dioxo
- Prior art date
Links
- -1 4-HYDROXYPHENYL Chemical class 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable de este: (ver Fórmula) donde R1 es un grupo alquilo C1-6; R2 y R3 son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un grupo alquilo C1-6; X2, X3 y X4 son iguales o diferentes entre sí y cada uno es un átomo de hidrógeno o un átomo de halógeno; y X5 es un átomo de hidrógeno o -P(=O) (OH)2 tiene una actividad de modulación de vía Wnt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013267687 | 2013-12-25 | ||
| PCT/JP2014/083932 WO2015098853A1 (ja) | 2013-12-25 | 2014-12-22 | （６Ｓ，９ａＳ）－Ｎ－ベンジル－６－［（４－ヒドロキシフェニル）メチル］－４，７－ジオキソ－８－（｛６－［３－（ピペラジン－１－イル）アゼチジン－１－イル］ピリジン－２－イル｝メチル）－２－（プロプ－２－エン－１－イル）－オクタヒドロ－１Ｈ－ピラジノ［２，１－ｃ］［１，２，４］トリアジン－１－カルボキサミド化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016007705A true MX2016007705A (es) | 2017-01-11 |
| MX365376B MX365376B (es) | 2019-05-31 |
Family
ID=53399298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016007705A MX365376B (es) | 2013-12-25 | 2014-12-22 | Compuesto de (6s,9as)-n-bencil-6-[(4-hidroxifenil)metil]-4,7-dioxo -8-({6-[3-(piperazin-1-il)azetidin-1-il]piridin-2-il}metil)-2-(pr op-2-en-1-il)-octahidro-1h-pirazino[2,1-c][1,2,4] triazina-1-carboxamida. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9174998B2 (es) |
| EP (1) | EP3088401B1 (es) |
| JP (1) | JP6085040B2 (es) |
| KR (1) | KR102307053B1 (es) |
| CN (1) | CN105873932B (es) |
| AR (1) | AR098908A1 (es) |
| AU (1) | AU2014371148B2 (es) |
| BR (1) | BR112016013572B1 (es) |
| CA (1) | CA2932435C (es) |
| CL (1) | CL2016001419A1 (es) |
| CY (1) | CY1122521T1 (es) |
| DK (1) | DK3088401T3 (es) |
| ES (1) | ES2728353T3 (es) |
| HR (1) | HRP20190908T1 (es) |
| HU (1) | HUE044541T2 (es) |
| IL (1) | IL245961A0 (es) |
| JO (1) | JO3809B1 (es) |
| LT (1) | LT3088401T (es) |
| ME (1) | ME03391B (es) |
| MX (1) | MX365376B (es) |
| MY (1) | MY173946A (es) |
| PE (1) | PE20160932A1 (es) |
| PH (1) | PH12016501079A1 (es) |
| PL (1) | PL3088401T3 (es) |
| PT (1) | PT3088401T (es) |
| RS (1) | RS58955B1 (es) |
| RU (1) | RU2669805C2 (es) |
| SG (1) | SG11201604496YA (es) |
| SI (1) | SI3088401T1 (es) |
| SM (1) | SMT201900306T1 (es) |
| TR (1) | TR201908392T4 (es) |
| TW (1) | TWI681961B (es) |
| UA (1) | UA116923C2 (es) |
| WO (1) | WO2015098853A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TH121482A (th) | 2009-08-19 | 2013-02-28 | นางสาวปัณณพัฒน์ เหลืองธาตุทอง | องค์ประกอบทางเภสัชกรรมที่ประกอบด้วยอนุพันธ์ของควิโนลีน |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| KR20230043234A (ko) | 2014-08-28 | 2023-03-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고순도의 퀴놀린 유도체 및 이를 제조하는 방법 |
| LT3263106T (lt) | 2015-02-25 | 2024-01-10 | Eisai R&D Management Co., Ltd. | Chinolino darinių kartumo sumažinimo būdas |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| MX373231B (es) * | 2015-06-16 | 2020-05-08 | Eisai R&D Man Co Ltd | Agente anticancerigeno. |
| KR102559211B1 (ko) * | 2015-06-23 | 2023-07-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | (6S,9aS)-N-벤질-8-({6-[3-(4-에틸피페라진-1-일)아제티딘-1-일]피리딘-2-일}메틸)-6-(2-플루오로-4-하이드록시벤질)-4,7-디옥소-2-(프로프-2-엔-1-일)헥사하이드로-2H-피라지노[2,1-c][1,2,4]트리아진-1(6H)-카복사마이드의 결정 |
| CA2994925C (en) | 2015-08-20 | 2023-08-29 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| CN108084067B (zh) * | 2016-11-22 | 2019-08-30 | 重庆圣华曦药业股份有限公司 | 一种立他司特中间体的制备方法 |
| US12303505B2 (en) | 2017-02-08 | 2025-05-20 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| BR112019023064A2 (pt) | 2017-05-16 | 2020-06-09 | Eisai R&D Man Co Ltd | tratamento de carcinoma hepatocelular |
| US20220409724A1 (en) | 2019-10-29 | 2022-12-29 | Eisai R&D Management Co., Ltd. | Combination of a pd-1 antagonist, a vegfr/fgfr/ret tyrosine kinase inhibitor and a cbp/beta-catenin inhibitor for treating cancer |
| CA3175150A1 (en) | 2020-03-12 | 2021-09-16 | 3+2 Pharma LLC | Cbp/catenin signaling pathway inhibitors and uses thereof |
| WO2021183791A1 (en) | 2020-03-12 | 2021-09-16 | City Of Hope | Wnt/cbp/catenin signaling pathway inhibitors and uses thereof |
| JPWO2022092294A1 (es) | 2020-10-30 | 2022-05-05 | ||
| US20240352020A1 (en) * | 2021-08-26 | 2024-10-24 | 3+2 Pharma, Llc | Pyrazole-containing cbp/catenin antagonists and uses thereof |
| WO2023038030A1 (ja) | 2021-09-08 | 2023-03-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 固形腫瘍治療用医薬組成物 |
| CN116262120A (zh) * | 2021-12-13 | 2023-06-16 | 上海中医药大学 | 特异性结合TRAF2的试剂在制备Wnt通路抑制剂中的应用 |
| WO2023140369A1 (en) * | 2022-01-18 | 2023-07-27 | Prism BioLab Co., Ltd. | Phosphoric acid derivatives |
| WO2023190748A1 (ja) | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| CN115784934A (zh) * | 2022-11-22 | 2023-03-14 | 上海吉奉生物科技有限公司 | 一种酪氨酸衍生物的合成方法 |
| AU2023439518A1 (en) | 2023-04-06 | 2025-08-28 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| WO2025174646A1 (en) * | 2024-02-12 | 2025-08-21 | Albert Einstein College Of Medicine | Inhibitors of beta-catenin c-terminal domain and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4387793B2 (ja) * | 2001-10-12 | 2009-12-24 | チョンウェ ファーマ コーポレーション | 逆向ターンミメティックおよびそれに関連した方法 |
| US8080657B2 (en) * | 2001-10-12 | 2011-12-20 | Choongwae Pharma Corporation | Compounds of reverse turn mimetics and the use thereof |
| US7671054B1 (en) | 2001-10-12 | 2010-03-02 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
| JP5530427B2 (ja) | 2008-06-06 | 2014-06-25 | 株式会社ＰＲＩＳＭ Ｐｈａｒｍａ | アルファへリックスミメティック及び関連の方法 |
| SG175045A1 (en) * | 2009-04-15 | 2011-11-28 | Jw Pharmaceutical Corp | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| ES2552462T3 (es) * | 2010-10-14 | 2015-11-30 | Jw Pharmaceutical Corporation | Nuevo compuesto de un mimético de giro inverso y un procedimiento de producción y uso del mismo |
| WO2012115286A1 (en) * | 2011-02-25 | 2012-08-30 | Prism Biolab Corporation | Alpha helix mimetics and methods relating thereto |
-
2014
- 2014-12-19 US US14/577,660 patent/US9174998B2/en active Active
- 2014-12-21 JO JOP/2014/0373A patent/JO3809B1/ar active
- 2014-12-22 HR HRP20190908TT patent/HRP20190908T1/hr unknown
- 2014-12-22 HU HUE14873998 patent/HUE044541T2/hu unknown
- 2014-12-22 UA UAA201606261A patent/UA116923C2/uk unknown
- 2014-12-22 RS RS20190665A patent/RS58955B1/sr unknown
- 2014-12-22 EP EP14873998.0A patent/EP3088401B1/en active Active
- 2014-12-22 PE PE2016000711A patent/PE20160932A1/es unknown
- 2014-12-22 CA CA2932435A patent/CA2932435C/en active Active
- 2014-12-22 JP JP2015554886A patent/JP6085040B2/ja active Active
- 2014-12-22 WO PCT/JP2014/083932 patent/WO2015098853A1/ja not_active Ceased
- 2014-12-22 AU AU2014371148A patent/AU2014371148B2/en active Active
- 2014-12-22 RU RU2016122867A patent/RU2669805C2/ru active
- 2014-12-22 DK DK14873998.0T patent/DK3088401T3/da active
- 2014-12-22 BR BR112016013572-5A patent/BR112016013572B1/pt active IP Right Grant
- 2014-12-22 AR ARP140104850A patent/AR098908A1/es active IP Right Grant
- 2014-12-22 PL PL14873998T patent/PL3088401T3/pl unknown
- 2014-12-22 PT PT14873998T patent/PT3088401T/pt unknown
- 2014-12-22 TW TW103144928A patent/TWI681961B/zh active
- 2014-12-22 ES ES14873998T patent/ES2728353T3/es active Active
- 2014-12-22 TR TR2019/08392T patent/TR201908392T4/tr unknown
- 2014-12-22 MY MYPI2016702025A patent/MY173946A/en unknown
- 2014-12-22 KR KR1020167015608A patent/KR102307053B1/ko active Active
- 2014-12-22 SM SM20190306T patent/SMT201900306T1/it unknown
- 2014-12-22 CN CN201480067017.7A patent/CN105873932B/zh active Active
- 2014-12-22 MX MX2016007705A patent/MX365376B/es active IP Right Grant
- 2014-12-22 LT LTEP14873998.0T patent/LT3088401T/lt unknown
- 2014-12-22 ME MEP-2019-158A patent/ME03391B/me unknown
- 2014-12-22 SG SG11201604496YA patent/SG11201604496YA/en unknown
- 2014-12-22 SI SI201431226T patent/SI3088401T1/sl unknown
-
2016
- 2016-06-01 IL IL245961A patent/IL245961A0/en active IP Right Grant
- 2016-06-07 PH PH12016501079A patent/PH12016501079A1/en unknown
- 2016-06-09 CL CL2016001419A patent/CL2016001419A1/es unknown
-
2019
- 2019-05-31 CY CY20191100578T patent/CY1122521T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12016501079A1 (en) | (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| PH12014501719B1 (en) | Pyridone derivatives | |
| NZ705705A (en) | Ret inhibitor | |
| PH12015501813A1 (en) | Monocyclic pyridine derivative | |
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| MY184306A (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
| PH12016502398A1 (en) | Dihydropyrimido loop derivative as hbv inhibitor | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| IN2015DN01035A (es) | ||
| MX2015012743A (es) | Compuesto de pirazol-amida y sus usos farmaceuticos. | |
| IN2014DN07509A (es) | ||
| IN2012DE00621A (es) | ||
| IN2012DE00620A (es) | ||
| MX2016001139A (es) | Derivado de pirazolilpirazol sustituido y uso del mismo como herbicida. | |
| MY185971A (en) | Pyranodipyridine compound | |
| MY178583A (en) | Hydantoin derivative | |
| MX358151B (es) | Derivado de sitaxentan. | |
| MY162945A (en) | Azole derivative | |
| MX355654B (es) | Derivado de paroxetina. | |
| WO2014125233A3 (fr) | Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle | |
| MX355337B (es) | Compuesto novedoso de ester de acido acetico o una sal del mismo. | |
| MY181470A (en) | Novel fluorinated benzilic acid ester compound and salt thereof | |
| JO3123B1 (ar) | مشتقات كينولين-تحتوي على مركبات دوائية | |
| MX345518B (es) | Compuestos analgesicos, metodos, y formulaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |